EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The impact of adjuvant radiotherapy on borderline and malignant phyllodes tumors of the breast

Amonthep Charoenyothakun, Kanjana Shotelersuk, Chonnipa Nantavithya, Kitwadee Saksornchai

Breast Cancer · 2025

DOI: 10.1007/s12282-025-01725-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer, 2025. Verfasst von Amonthep Charoenyothakun und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Radiation Oncology, Department of Radiology, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand. Hauptthemen laut MEDLINE: Phyllodes Tumor, Breast Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Borderline and malignant phyllodes tumors (PTs) are rare fibroepithelial breast neoplasms associated with a high risk of locoregional recurrence (LRR). Although adjuvant radiation therapy (RT) is increasingly used, its clinical benefit remains uncertain. This study aimed to assess the impact of RT and identify factors associated with LRR in patients with borderline and malignant PTs.

Methods

A retrospective review was conducted on 102 patients (50 borderline, 52 malignant PTs) who underwent surgery between 2012 and 2021. Clinical, pathological, and treatment data were analyzed. The primary endpoint was LRR. Kaplan–Meier and Cox regression models were used to assess recurrence and risk factors.

Results

Median follow-up was 4.3 years. Malignant PTs were more likely to be > 10 cm (63.5% vs. 22%), undergo mastectomy (75% vs. 11%), and receive adjuvant RT (78.9% vs. 8%) compared to borderline PTs (all P < 0.001). Among patients without RT, malignant PTs had a significantly higher LRR than borderline PTs (36.4% vs. 4.4%, P < 0.010). In malignant PTs, RT was associated with a lower LRR (12.2% vs. 36.4%), though not statistically significant (P = 0.081). Tumor subtype was the only independent predictor of LRR (P = 0.011). Among malignant PTs who received RT, treatment initiation beyond 12 weeks post-surgery was associated with increased LRR (P = 0.009). Radiation technique, dose, and use of bolus were not significantly associated with LRR.

Conclusion

Malignant PTs demonstrated higher LRR than borderline PTs. While the benefit of RT was not statistically significant, a trend toward reduced recurrence was observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phyllodes TumorBreast NeoplasmsNeoplasm Recurrence, LocalHumansFemaleRadiotherapy, AdjuvantRetrospective StudiesMiddle AgedAdultMastectomyFollow-Up StudiesAgedKaplan-Meier EstimateYoung AdultRisk Factors

Stichwörter der Autor:innen

BreastPhyllodes tumorRadiotherapy

Autor:innen und Institutionen

  • Division of Radiation Oncology, Department of Radiology, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
  • Division of Radiation Oncology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
  • Division of Radiation Oncology, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. kitwadee.s@chula.ac.th.

Zitieren

APA

Charoenyothakun, A., Shotelersuk, K., Nantavithya, C., & Saksornchai, K. (2025). The impact of adjuvant radiotherapy on borderline and malignant phyllodes tumors of the breast. Breast Cancer. https://doi.org/10.1007/s12282-025-01725-3

Vancouver

Charoenyothakun A, Shotelersuk K, Nantavithya C, Saksornchai K. The impact of adjuvant radiotherapy on borderline and malignant phyllodes tumors of the breast. Breast Cancer. 2025. doi:10.1007/s12282-025-01725-3

BibTeX
@article{Charoenyothakun2025,
  author = {Charoenyothakun, Amonthep and Shotelersuk, Kanjana and Nantavithya, Chonnipa and Saksornchai, Kitwadee},
  title = {The impact of adjuvant radiotherapy on borderline and malignant phyllodes tumors of the breast},
  journal = {Breast Cancer},
  year = {2025},
  doi = {10.1007/s12282-025-01725-3}
}
Kostenlos starten →